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ABSTRACT 
Nanotechnology is rapidly expanding area in the field of science that helps us to manipulate matter at the atomic and molecular level 
thus having varied and new properties with huge potential. It is the study of extremely small particles ranging from 1-1000 nm. This 
small size imparts the nanoscale devices their applications in medicine and physiology while permitting them to interact with cells 
and tissues at subcellular level, with bioreceptors on both the surface and inside of cell membrane thus providing a high degree of 
functional specificity to the systems. Nanodevices in medicine involves applications of nanoparticles, polymeric micelles, 
dendrimers, nanotubes, inorganic nanoparticles, nanocrystals and quantam dots which are currently under development as well as 
constitute the major part of  longer range research. Improvement in drug solubility, high drug loading capacity, ease of surface 
modification, increase in blood circulation time, controlled release and highly site-specific targeted delivery are the advantages 
responsible for such wide applications of these nanomaterials. The applications include drug and gene delivery to specific site, 
delivery and detection of specific proteins, biological imaging and biosensors, DNA probing, tissue engineering, pathogens and 
tumor detection. This article has made an attempt to cover the few insights of nanotechnology as an interesting approach and 
illustrates various nanosystems along with their advantages, applications and well approved commercially available products.  
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INTRODUCTION 
Nanotechnology is the branch of science which deals with 
the study of design, creation, synthesis and précised 
manipulation of matter at a nano scale1. The word “nano” is 
derived from the Greek word “dwarf”. One nanometer 
(nm) is a unit in metric system which is equal to one 
billionth of a meter (10-9 m)2. At this size, nano materials 
can have different and enhanced properties compared with 
larger size of the same material. The nanoparticles (NPs) 
are nanostructure particles in the size ranging from 1-1000 
nm. They provide a variety of surprising and interesting 
uses in biomedicine by overcoming the many biological 
and biomedical barriers3. 
POLYMERIC MICELLES  
The earliest concept of polymeric micelles (PM) was first 
introduced in 1984 by Ringsdorf et al for drugs having low 
solubility4. They are self-assembled nanostructures 
micelles ranges from 10 to 200 nm, made up from 
amphiphilic block copolymers in aqueous solution5 as 
represented in Figure: 1. The formation of micelles starts 
at critical micelle concentration (CMC) of copolymer in 
aqueous solution. The non-polar part of block copolymers 
combine to form a core-shell structure. Thus, the processes 
of micelles formation take place by decrease in free energy 
of system6.  
Polymeric micelles have a great potential to encapsulate a 
drug which exhibit poor water solubility and low 
bioavailability. In polymeric micelles, the drugs are 
encapsulated by various methods such as dialysis method7,  
solvent evaporation method8,9 and solid dispersion 
method10. Other methods mentioned in literatures are 
direct dissolution11, and interpolymer complexation12. 
Most of micelles based formulations are in final stage of 
clinical trials & under consideration of FDA. Already FDA 
approved products includes Cernevit™-12 (1999) as a 
multivitamin Intravenous infusion and Estrasorb™ (1975) 
for menopause problems as topical formulation13. The 
overall ability of polymeric micelles is dependent upon the 
interaction of hydrophobic segment and the polarity of 
drug molecule. Commonly used hydrophobic polymers are 
selected on the basis of their biocompatibility and non-
toxicity. These includes Pluronics®14; poly (esters)15,  
poly(ε-caprolactone)16  and phospholipids and lipid-
derivatives.  Their therapeutic potential includes the 
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delivery of antitumor drugs alone or as a conjugate to 
specific site17. Other advantages includes, stable than 
surfactant, prolong blood circulation times and protection 
from mononuclear phagocytic system18. 
 
 
Figure 1: Schematic representation of formation of polymeric micelles 
 
DENDRIMERS 
Dendrimers are polymer-based tree-like, star-shaped 
macromolecules with doubles or triples branching units as 
reported by Vogtle et al in 197819. They are also known as 
“arboróis”, “cascade molecules” and polymers of the 21st 
century20. They have great potential in biomedical research 
with ease of modification, simple preparation method and 
size ranged 2 to 10 nm for drug targeting. Modification in 
degree of branching may offer encapsulation possibility for 
variety of drug molecules21. They have a unique 
architectural design with high degree of branching with 
internal hydrophobicity suitable for hydrophobic drug as 
shown in Figure 2. 
 
 
Figure 2: Schematic representation of dendrimers branching system (A) drug attached terminal surface (B) drug 
attached to interior terminal branches 
 
Dendrimers consisted of an initiator core, interior layer 
and  layer for terminal functional group attached. 
Preparation starts from attachment of carbon and other 
elements to an atom like nitrogen followed by repeated 
addition of branching molecules by certain chemical 
reactions. They are three dimensional carrier systems with 
many functional surface groups; drug can attach to the 
interior or attached to the surface of dendrimers. The 
association of drug with dendrimers takes place by 
physical entrapment, covalent linkage to the surface or as 
drug conjugates22. The resulting dendrimers have the size 
which is suitable for blood circulation. They can be 
synthesized and designed into variety of structures due to 
their feasible topology, functionality and dimensions, ideal 
for intravenous, oral, transdermal, pulmonary and ocular 
routes administration23.  They are ideally used for delivery 
of oligonucletide, specific receptor site drug targeting, and 
also for less water soluble drugs24. The overall properties 
of dendrimers are affected by pH, salt effect, nature of 
solvent and concentration of dendrimer25. Examples of 
dendrimer based products in market are  VivaGel® BV, 
Priostar®, Stratus CS®, Starburst®, Priofect® and 
SuperFect®21. 
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Advantages of dendrimers26, 27  
1. Size range from 1 - 100 nm can overcome the problem 
of uptake by reticulum endothelium.  
2. Lower polydispersity index 
3. Outer surface can be utilized for attachment of vector 
devices for drug targeting  
4. Can be prepared for stimuli responsive drug release 
system 
5. Better enhanced permeability and retention effect, can 
be effectively used for tumour targeting 
NANOTUBES 
Carbon nanotubes (CNT) are nanostructure carrier 
systems that have high drug loading potential and with 
high cell penetration properties. They can act as a drug 
container, because of their tube like structure which is 
made up from one or more layers of grapheme. Sumio 
Iijima, a Japanese physicist invent the carbon nanotubes in 
1991 and received a number of prestigious awards and 
recognition for his work28. Carbon nanotubes are classified 
as single-walled nanotubes (SWNT) and multi walled 
carbon nanotubes (MWNTs) as shown in Figure 3. They 
have been proven for better bioavailability, decreased 
toxicity and sustained half-life29. Carbon nanotubes have 
numerous biomedical applications and ideal carries for the 
delivery of proteins. The major focused area of carbon 
nanotubes is delivery of anticancer agents due to their 
unique needle-like shapes which enable them to adsorb or 
covalently bind to the target cell such as delivery of 
doxorubicin, camptothecin, carboplatin, cisplatin and  
paclitaxel 30.  
  
 
Figure 3: Schematic representation of (a) single-walled nanotubes (SWNT) and (b) multi walled carbon nanotubes 
(MWNTs)  
 
Due to their high surface area to volume ratio, they provide 
a good platform for better loading of various drugs and 
chemicals30, 31. The recent biomedical applications of 
carbon nanotubes are represented in Figure 4. 
 
 
Figure 4: Application of functionalized carbon nanotubes 
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INORGANIC NANOPARTICLES 
Inorganic nanoparticles are commonly used for cellular 
delivery of gene and protein based drugs. Most inorganic 
nanoparticles belongs to metals (gold, silver), metal salts 
and metal oxides with chemical or biological modification 
for their cellular delivery32. They are biocompatibility, and 
have affinity for different bio-molecules and thus site-
specificity33. Gold nanoparticles are considered as potential 
carrier for intracellular targeting vector due size range of 
0.8 and 200 nm, surface modification and possess visible 
light extinction behavior for drug tracking purpose in the 
cells. Similarly, silver nanoparticles have gained the 
attention with unique properties to develop products for 
medical and industrial purposes. They have ideal optical, 
electrical and thermal properties that have impact on their 
application in medical device, optical sensors and in drug 
delivery systems10,34,  
Advantages of inorganic nanoparticle32, 35, 36 
1. Ease of surface modification and conjugation based on 
various structures and nature of drugs 
2. High loadings capacity 
3. Controlled release kinetics based on the material or 
capping method  
4. Provide protection from various factors until not 
released, hence improved the in vivo bioavailability 
5. Suitable for magnetically or antibody-targeted 
targeted delivery to specific tissue or sites. 
6. Can be use as biomarkers in the diagnosis of heart 
diseases, cancers, and other conditions 
7. Suitable for biological imaging and biosensors 
applications 
8. Use as probes for microscopy such as transmission 
electron microscopy 
NANOCRYSTALS 
Nanocrystals are crystalline aggregates of the drugs 
surrounded by a thin coating of hydrophilic layer of 
surfactant. The hydrophilic layer helps in drug bio-
distribution and bioavailability and control the aggregation 
of the crystalline drug material during storage35. The 
concept of formation of nanocrystal is extensively evolved 
for solubility enhancement. Nanocrystal technology 
improved dissolution rate, high drug loading, improved 
oral absorption and bioavailability37. Commonly used 
methods for preparation of nanocrystals are 
nanoprecipitation, milling, homogenization38, Spray 
drying39, Nanopure® XP technology40 and Spray Freezing 
into Liquid technology41. 
Advantages of nanocrystals42  
1. Improved rate of absorption 
2. Increased over all surface area 
3. Enhanced solubility  
4. Increased the rate of dissolution 
5. Suitable for various administration routes 
6. Further processing in various dosages form such as 
tablets, capsules 
7. Increased blood circulation time 
8. Can be formulate as hybrid nanocrystals for both 
diagnostic and therapeutic purpose 
QUANTUM DOTS 
Quantum dots are semiconducting nanoparticles being 
illuminated by light and characteristically used for bio-
imaging applications. They present many intrinsic photo-
physical properties that are desirable for the imaging and 
drug targeting purposes. Quantum mean amount, a discrete 
unit commonly used to represent change in energy or 
matter involved in an interaction43. Quantum dots 
generally have metalloid crystalline core which are 
enclosed by a shell and when exposed to ultraviolet light, 
they emit the signal of visible light which can determine a 
image of source44. Quantum dots are 20-100 times brighter 
than traditionally used dyes for in vitro imaging45. They 
play a vital role in investigation of intracellular moment of 
nanosized structures coupled with help of confocal 
microscopy or transmission electron microscopy. Quantum 
dots are ideal tool for in vivo animal imaging but limited in 
human studies due to heavy metal toxicity46. Major 
applications of quantum dots includes, labeling cells, neural 
imaging, lymph node mapping, vasculature imaging, use as 
biomarkers for cancer detection, photodynamic cancer 
therapy, and as a delivery systems45, 47,. 
Advantages of quantum dots43  
1. Longer-lasting photostability  
2. Broader excitation spectra and a well defined emission 
peak 
3. More stable than organic dyes  
4. Can be modified with biomaterials 
5. Better contrast for electron microscope  
6. Real-time tracking of molecules and cells 
7. Easy to make and produce several different colors 
CONCLUSION 
Nanomaterials have unique physicochemical and biological 
properties which help to overcome the limitations of other 
conventional dosage forms. It has been gaining a 
widespread popularity due to its promising usage in 
disease diagnosis and treatment with high efficacy as no 
data is available about its any harmful effect to the best of 
our knowledge. The advantageous properties are basically 
due to their peculiar size and shape which accounts for the 
high attention of researchers for their use towards every 
aspect of human health. Thus, nanotechnology is 
revolutionizing the advances in medicine and research 
both in laboratories and clinically. 
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